Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis.

Palaparthy R, Rehman MI, von Richter O, Yin D.

Expert Opin Biol Ther. 2019 Oct;19(10):1065-1074. doi: 10.1080/14712598.2019.1635583. Epub 2019 Jul 8.

PMID:
31284794
2.

Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar.

von Richter O, Lemke L, Haliduola H, Balfour A, Zehnpfennig B, Skerjanec A, Jauch-Lembach J.

Expert Opin Biol Ther. 2019 Oct;19(10):1057-1064. doi: 10.1080/14712598.2019.1603959. Epub 2019 Apr 19.

PMID:
31002537
3.

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.

Alten R, Batko B, Hala T, Kameda H, Radominski SC, Tseluyko V, Babic G, Cronenberger C, Hackley S, Rehman M, von Richter O, Zhang M, Cohen S.

RMD Open. 2019 Mar 28;5(1):e000876. doi: 10.1136/rmdopen-2018-000876. eCollection 2019.

4.

Drug-Drug Interactions: Progress Over the Past Decade and Looking Ahead to the Future.

Derendorf H, von Richter O, Hermann R, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2019 Jun;105(6):1289-1291. doi: 10.1002/cpt.1410. Epub 2019 Apr 12. No abstract available.

PMID:
30977519
5.

GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.

von Richter O, Lemke L, Haliduola H, Fuhr R, Koernicke T, Schuck E, Velinova M, Skerjanec A, Poetzl J, Jauch-Lembach J.

Expert Opin Biol Ther. 2019 Oct;19(10):1075-1083. doi: 10.1080/14712598.2019.1571580. Epub 2019 Jan 30.

PMID:
30698045
6.

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide.

Lüpfert C, Dyroff M, von Richter O, Gallemann D, El Bawab S, Dolgos H, Jung D, Hecht S, Johne A.

CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):829-837. doi: 10.1002/psp4.12360. Epub 2018 Oct 31.

7.

Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice: Drug-Drug and Food-Drug Interactions.

Hermann R, Derendorf H, von Richter O, Rostami-Hodjegan A.

J Clin Pharmacol. 2018 Jun;58(6):704-716. doi: 10.1002/jcph.1088. Epub 2018 Mar 7. No abstract available.

PMID:
29513896
8.

State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015.

Poetzl J, Arlt I, von Richter O, Wöhling H, Afonso M, Schaffar G.

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e130-e132. doi: 10.1111/jdv.14632. Epub 2017 Nov 6. No abstract available.

PMID:
29024096
9.

Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.

Kropeit D, von Richter O, Stobernack HP, Rübsamen-Schaeff H, Zimmermann H.

Clin Pharmacol Drug Dev. 2018 Jan;7(1):9-21. doi: 10.1002/cpdd.388. Epub 2017 Oct 2.

PMID:
28967706
10.

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.

von Richter O, Skerjanec A, Afonso M, Sanguino Heinrich S, Poetzl J, Woehling H, Velinova M, Koch A, Kollins D, Macke L, Wuerth G.

Br J Clin Pharmacol. 2017 Apr;83(4):732-741. doi: 10.1111/bcp.13170. Epub 2016 Dec 16.

11.

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

von Richter O, Massimini G, Scheible H, Udvaros I, Johne A.

Br J Clin Pharmacol. 2016 Dec;82(6):1498-1508. doi: 10.1111/bcp.13078. Epub 2016 Sep 19.

12.

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F.

Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19.

13.

Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.

Becker A, von Richter O, Kovar A, Scheible H, van Lier JJ, Johne A.

J Clin Pharmacol. 2015 Jul;55(7):815-24. doi: 10.1002/jcph.482. Epub 2015 Mar 23.

PMID:
25683324
14.

Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions.

Hermann R, von Richter O.

Planta Med. 2012 Sep;78(13):1458-77. doi: 10.1055/s-0032-1315117. Epub 2012 Aug 1. Review.

15.

Calcein assay: a high-throughput method to assess P-gp inhibition.

Glavinas H, von Richter O, Vojnits K, Mehn D, Wilhelm I, Nagy T, Janossy J, Krizbai I, Couraud P, Krajcsi P.

Xenobiotica. 2011 Aug;41(8):712-9. doi: 10.3109/00498254.2011.587033. Epub 2011 Jun 9.

PMID:
21657832
16.

Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.

Nassr N, Huennemeyer A, Herzog R, von Richter O, Hermann R, Koch M, Duffy K, Zech K, Lahu G.

Br J Clin Pharmacol. 2009 Oct;68(4):580-7. doi: 10.1111/j.1365-2125.2009.03478.x.

17.

Multidrug resistance protein 2-mediated estradiol-17beta-D-glucuronide transport potentiation: in vitro-in vivo correlation and species specificity.

Herédi-Szabó K, Glavinas H, Kis E, Méhn D, Báthori G, Veres Z, Kóbori L, von Richter O, Jemnitz K, Krajcsi P.

Drug Metab Dispos. 2009 Apr;37(4):794-801. doi: 10.1124/dmd.108.023895. Epub 2008 Dec 31.

PMID:
19118132
18.

A novel screening strategy to identify ABCB1 substrates and inhibitors.

von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, Zech K.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26. doi: 10.1007/s00210-008-0345-0. Epub 2008 Aug 29.

PMID:
18758752
19.

Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.

Lahu G, Huennemeyer A, von Richter O, Hermann R, Herzog R, McCracken N, Zech K.

J Clin Pharmacol. 2008 Nov;48(11):1339-49. doi: 10.1177/0091270008321941. Epub 2008 Aug 29.

PMID:
18757786
20.

Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.

von Richter O, Lahu G, Huennemeyer A, Herzog R, Zech K, Hermann R.

Clin Pharmacokinet. 2007;46(7):613-22.

PMID:
17596106
21.

ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions.

Glavinas H, Kis E, Pál A, Kovács R, Jani M, Vági E, Molnár E, Bánsághi S, Kele Z, Janáky T, Báthori G, von Richter O, Koomen GJ, Krajcsi P.

Drug Metab Dispos. 2007 Sep;35(9):1533-42. Epub 2007 May 30.

PMID:
17537873
22.

Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.

Nassr N, Lahu G, Hünnemeyer A, von Richter O, Knoerzer D, Reutter F, Zech K, Hermann R.

J Clin Pharmacol. 2007 May;47(5):660-6. Epub 2007 Mar 20. No abstract available.

PMID:
17374735
23.

Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.

Pál A, Méhn D, Molnár E, Gedey S, Mészáros P, Nagy T, Glavinas H, Janáky T, von Richter O, Báthori G, Szente L, Krajcsi P.

J Pharmacol Exp Ther. 2007 Jun;321(3):1085-94. Epub 2007 Mar 8.

PMID:
17347325
24.

Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.

Nassr N, Lahu G, von Richter O, Reutter F, Knoerzer D, Zech K, Erb KA, Schug B, Blume H, Hermann R.

Br J Clin Pharmacol. 2007 Mar;63(3):365-70. Epub 2006 Sep 29.

25.

Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype.

Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E, Ingelman-Sundberg M, Hammons GJ, Lyn-Cook BD, Kadlubar FF, Saldana SN, Sorter M, Vinks AA, Nassr N, von Richter O, Jin L, Nebert DW.

Pharmacogenet Genomics. 2006 May;16(5):359-67.

PMID:
16609368
26.

Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity.

Westlind-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, Nassr N, Zech K, Ingelman-Sundberg M, von Richter O.

Clin Pharmacol Ther. 2006 Apr;79(4):339-49. Epub 2006 Feb 28.

PMID:
16580902
27.

Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6).

von Richter O, Pitarque M, Rodríguez-Antona C, Testa A, Mantovani R, Oscarson M, Ingelman-Sundberg M.

Pharmacogenetics. 2004 Jun;14(6):369-79.

PMID:
15247629
28.

Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.

von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT.

Clin Pharmacol Ther. 2004 Mar;75(3):172-83.

PMID:
15001968
29.

A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity.

Pitarque M, von Richter O, Rodríguez-Antona C, Wang J, Oscarson M, Ingelman-Sundberg M.

Hum Mutat. 2004 Mar;23(3):258-66.

PMID:
14974084
30.

Differential expression and function of CYP2C isoforms in human intestine and liver.

Läpple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, Eichelbaum M, Kivistö KT.

Pharmacogenetics. 2003 Sep;13(9):565-75.

PMID:
12972955
31.

Tissue-specific regulation of canine intestinal and hepatic phenol and morphine UDP-glucuronosyltransferases by beta-naphthoflavone in comparison with humans.

Bock KW, Bock-Hennig BS, Münzel PA, Brandenburg JO, Köhle CT, Soars MG, Riley RJ, Burchell B, von Richter O, Eichelbaum MF, Swedmark S, Orzechowski A.

Biochem Pharmacol. 2002 May 1;63(9):1683-90.

PMID:
12007571
32.

Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters.

Glaeser H, Drescher S, van der Kuip H, Behrens C, Geick A, Burk O, Dent J, Somogyi A, Von Richter O, Griese EU, Eichelbaum M, Fromm MF.

Clin Pharmacol Ther. 2002 Mar;71(3):131-40.

PMID:
11907487
33.

Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique.

von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, Dent J, Somogyi AA, Eichelbaum M.

Clin Pharmacol Ther. 2001 Sep;70(3):217-27.

PMID:
11557909
34.

Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity.

Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M.

Biochem Biophys Res Commun. 2001 Jun 8;284(2):455-60.

PMID:
11394901
35.

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.

Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W.

Clin Pharmacol Ther. 2000 Oct;68(4):345-55.

PMID:
11061574
36.

In vitro interaction of codeine and diclofenac.

Ammon S, von Richter O, Hofmann U, Thon KP, Eichelbaum M, Mikus G.

Drug Metab Dispos. 2000 Oct;28(10):1149-52.

PMID:
10997932
37.

Rapid and highly sensitive method for the determination of verapamil, [2H7]verapamil and metabolites in biological fluids by liquid chromatography-mass spectrometry.

von Richter O, Eichelbaum M, Schönberger F, Hofmann U.

J Chromatogr B Biomed Sci Appl. 2000 Jan 28;738(1):137-47.

PMID:
10778935
38.

Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.

Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF.

J Pharmacol Exp Ther. 2000 May;293(2):376-82.

PMID:
10773005
39.

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8.

40.

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK.

J Clin Invest. 1999 Jul;104(2):147-53. Erratum in: J Clin Invest 2002 Aug;110(4):571.

41.

Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.

Schwarz UI, Gramatté T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W.

Clin Pharmacol Ther. 1999 Mar;65(3):283-90.

PMID:
10096260

Supplemental Content

Loading ...
Support Center